Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18427623 | High Efficiency Methods for Isolating Proteins | January 2024 | May 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18179057 | COMBINATIONS WITH AN ANTI HUMAN CD39 ANTIBODY, AN ANTI HUMAN PD-1 ANTIBODY, AND CHEMOTHERAPY IN GASTRIC CANCER | March 2023 | May 2025 | Abandon | 26 | 1 | 0 | No | No |
| 17741234 | ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF | May 2022 | June 2025 | Allow | 37 | 1 | 1 | No | No |
| 17626239 | Caninized Antibodies Against Canine CTLA-4 | January 2022 | June 2025 | Allow | 41 | 0 | 1 | No | No |
| 17620496 | MONOCLONAL ANTIBODIES AGAINST JC VIRUS | December 2021 | May 2025 | Allow | 40 | 0 | 1 | No | No |
| 17608992 | CIRCULATING TUMOR CELL BASED BIOMARKER COMPOSITION FOR DIAGNOSIS AND PROGNOSIS OF METASTATIC PROSTATE CANCER | November 2021 | March 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17608381 | NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE | November 2021 | December 2024 | Allow | 37 | 0 | 0 | Yes | No |
| 17604294 | OVEREXPRESSION OF IMMUNOPROTEASOME IN HOST CELLS FOR GENERATING ANTIGEN-PRESENTING CELLS | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17294713 | METHODS FOR IMPROVING THE EFFICACY OF A SURVIVIN THERAPEUTIC IN THE TREATMENT OF TUMORS | October 2021 | June 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17491853 | SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION | October 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17600805 | ANTIBODY VARIANTS WITH PH-DEPENDENT ANTIGEN BINDING FOR SELECTIVE TARGETING OF SOLID TUMORS | October 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17436857 | ANTI-CANCER COMBINATION THERAPIES COMPRISING CTLA-4 AND PD-1 BLOCKING AGENTS | September 2021 | March 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17311226 | Primary NK CAR Constructs And Methods | June 2021 | June 2025 | Allow | 48 | 2 | 1 | No | No |
| 17299147 | PCSK9 ANTAGONISTS | June 2021 | April 2025 | Allow | 46 | 1 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner PETERS, ALEC JON works in Art Unit 1641 and has examined 13 patent applications in our dataset. With an allowance rate of 69.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner PETERS, ALEC JON's allowance rate of 69.2% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PETERS, ALEC JON receive 0.62 office actions before reaching final disposition. This places the examiner in the 5% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by PETERS, ALEC JON is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +44.4% benefit to allowance rate for applications examined by PETERS, ALEC JON. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 97% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.